MRFR Year End Sale
Liquid Biopsy Market Research Report - Global Forecast to 2030

Liquid Biopsy Market Research Report: Information by Biomarker Types (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (CTDNA), Extracellular Vesicles (EVS) and other Biomarker (Circulating RNA and Proteins)), Application (Cancer Therapeutic Application, Reproductive Health and Other Therapeutic Application), Sample (Blood Sample, Urine Sample and other), End User (Hospitals and Laboratories, Academic and Research Centers and other End Users) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) - Global Forecast to

ID: MRFR/HC/0239-CR | February 2021 | Region: Global | 171 Pages         

Liquid Biopsy Market

Global liquid biopsy market is expected to exhibit 12.4% CAGR to reach USD 13.8 Billion during the forecast period 2022-2030


By Biomarker Types Circulating Tumor Cells Circulating Tumor DNA Extracellular Vesicles other Biomarker
By Application Cancer Therapeutic Application Reproductive Health Other Therapeutic
By Sample Blood Sample Urine Sample other

Key Players

  • Guardant Health Inc.(US)
  • Trovagene Inc.(California)
  • RainDance Technologies Inc. US)
  • Agena Bioscience Inc. (California)


  • Comparatively Painless And Non-Invasive Technique
  • Early Real Time High Precision Detection Of Diseases
  • The Recent Technological Advancements Has Increased The Appeal Of Liquid Biopsy
Speak to Analyst Request a Free Sample

Liquid Biopsy Market Overview

The Liquid Biopsy Market is expected to reach USD 13.8 billion by 2030 at 12.4% CAGR during the forecast period 2022-2030. A liquid biopsy is a largely non-invasive, sampling and analysis of liquid state biological tissue for diagnostic and monitoring diseases such as cancer. Liquid biopsy is the direct clinical application of two advances in medical science, namely, human genome sequencing and rising sensitivity of detecting techniques and assays.

Liquid biopsy capitalizes on the qualitative and quantitative difference between different biomarkers such as cell-free DNA, circulating tumor cells (CTCs), cell-free RNA (cfRNA) fragments, methylated ctDNA, and miRNA in a patient's blood. Although some of these fragments are released even during other conditions such as trauma, there exists a quantitative difference in the form of their composition and concentration as well as their degree of fragmentation.

Liquid Biopsy Market Dynamics

Liquid biopsies avoid the painful extraction of the tissue sample and thereby eliminate the pain associated with the procedure. For instance, a majority of liquid samples used in the procedure are blood and urine and are easily collected without much pain. A few examples however involve painful procedure such as spinal fluid. Thus, liquid biopsy reduces the apprehension of patients regarding pain. It also provides a safe and effective method for patients for whom a tissue biopsy is not possible due to associated risks, such as lung cancer patients with tumors too dangerously close to the heart.

Liquid Biopsy Market Segmentation

The global liquid biopsy market has been segmented into biomarker types, application, samples, and end user. 

Based on biomarker types, the global market is segmented into circulating tumor cells (CTCS), circulating tumor DNA (CTDNA), extracellular vesicles (EVS), and others.

Based on application, the global market has been segmented into cancer, reproductive health, and others.

Based on sample, the global market is segmented into blood sample, urine sample, forensic, and other sample.

Based on end user, the global market is segmented into hospitals and laboratories, academic and research centers, and other end users. Advances in detection technologies such as digital PCR, advanced cell capture technology, and multi-panel detection were the other driving factors for the commercial application of the technology.

Liquid Biopsy Market Key Players

The major players in the global liquid biopsy market are Guardant Health, Inc. (US), Trovagene, Inc. (California), RainDance Technologies, Inc. (US), Agena Bioscience Inc. (California), Admera Health (US), Biocept, Inc. KGaA (US), Circulogene Theranostics (Alabama), Inivata Ltd (UK), SAGA Diagnostics AB (Sweden), and Exosome Diagnostics (Massachusetts).

Some of the key strategies followed by the players operating in the global market are adopting various strategies to expand their global liquid biopsy business and enhance their market share.

Liquid Biopsy Market Regional Analysis

The global liquid biopsy in the healthcare market, on the basis of region, is segmented into North America, Europe, Asia-Pacific, and Middle East & Africa.

North America accounted for the largest market share while Asia-Pacific is the fastest-growing market. The technology of liquid biopsy was developed in the US and several European countries, which is reflected in the dominance of these two regions in their respective market share. The European market is projected to grow at the highest CAGR. The venture capital available to life sciences companies has more than doubled from 2001 to 2010. In Europe, the UK accounts for almost 20% of all investments, and almost 20% of the UK venture capital was invested in the healthcare sector.

Asia-Pacific is the fastest-growing market and is expected to grow at a exponentail CAGR during the forecasted period. The Middle East & Africa is expected to have a limited market but steady growth. In 2012, 14 million new cases and 8.2 million cancer-related deaths were reported worldwide, and this number is projected to reach 22 million within the next two decades. Africa, Asia-Pacific, and Central and South America account for almost 2/3rd of the cases and 3/4th of the deaths.

Key Updates

  • Guardant Health, Inc. and MD Anderson announced their partnership to make comprehensive liquid biopsy part of oncology standard of care.

  • Agena Bioscience, Inc. launched high sensitivity and multiplexed genetic testing product for targeted analysis of solid tumors. iPLEX HS chemistry enables detection of genetic variants, including somatic mutations, translocations, and indels, that are present at levels as low as 1% in frequency.

  • Inivita Ltd raised USD 31.5 million in a Series A fundraising from existing investors such as Imperial Innovations, Cambridge Innovation Capital, and Johnson & Johnson Innovation - JJDC, Inc. The new investor was Woodford Patient Capital Trust.

Liquid Biopsy Market Segmental Overview

Global Market by Test Type

  • Circulating Tumor Cells (CTCs)

  • Circulating Tumour DNA (CtDNA)

  • Extracellular Vesicles (EVs)

  • Other Biomarker (Circulating RNA and Proteins)

Global Market by Application

  • Cancer Consumables

  • Reproductive Health

  • Other Therapeutic Application

Global Market by Sample

  • Blood Sample

  • Urine Sample

  • Other Sample

Global Market by End Users

  • Hospitals and Laboratories

  • Academic and Research Centres

  • Other End Users

Global Market by Region

  • North America

    • US

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Middle East & Africa

    • UAE

    • Saudi Arabia

    • Egypt

    • Rest of Middle East & Africa

Available Additional Customizations

  • Additional Companies

    • LungLife AI, Inc.

    • NeoGenomics Laboratories, Inc.

    • QIAGEN

    • CellMax Life

    • ANGLE plc

    • Thermo Fisher Scientific Inc.

Intended Audience

  • Clinical laboratories

  • Research and academic institutes

  • Government research organizations

  • Hospitals and clinics

  • Regulatory agencies

  • Physician laboratories

Report Scope:

Report Attribute/Metric Details
  Market Size   USD 13.8 Billion
  CAGR   12.4%
  Base Year   2021
  Forecast Period   2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Biomarker Types, Application, Sample and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Guardant Health, Inc. (US), Trovagene, Inc. (California), RainDance Technologies, Inc. (US), Agena Bioscience Inc. (California), Admera Health (US), Biocept, Inc. KGaA (US), Circulogene Theranostics (Alabama), Inivata Ltd (UK), SAGA Diagnostics AB (Sweden), and Exosome Diagnostics (Massachusetts)
  Key Market Opportunities

  • Growing Collaboration Between Companies Has Become The Entrance Gateway For New Firms
  • Funding From Public Organizations Is A Good Strategy To Reduce Developments Costs
  • Rise In Research And Developments Investment
  • Developing Economies Provide An Unserved Market For Liquid Biopsy
  • Growing Trend Of Start-Ups And Venture Investment In The Field Of Liquid Biopsy
  •   Key Market Drivers

  • Comparatively Painless And Non-Invasive Technique
  • Early Real Time High Precision Detection Of Diseases
  • Useful For Designing Effective Treatment Strategies Based On The Real Time Molecular Assessment For The Progression Of The Disease
  • Rise In Cases Of Cancer And Other Diseases
  • Lifestyle Changes And Environmental Factors
  • Other Advantages Over Other Techniques
  • The Recent Technological Advancements Has Increased The Appeal Of Liquid Biopsy

  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The liquid biopsy market is projected to reach a valuation of USD 13.8 Billion by 2030.

    The global liquid biopsy market is projected to grow at approximately 12.4% CAGR during forecast period (2022-2030).

    North America holds the largest share in the global liquid biopsy market followed by Europe and Asia Pacific, respectively.

    Trovagene, Inc. (California), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), Admera Health (US), Agena Bioscience Inc. (California), Biocept, Inc. KGaA (US), Inivata Ltd (UK), Circulogene Theranostics (Alabama), Exosome Diagnostics (Massachusetts), and SAGA Diagnostics AB (Sweden), are some of the major players operating in the liquid biopsy market.